title: Expression of A disintegrin and metalloprotease 8 is associated with cell growth and poor survival in colorectal cancer.
abstract: BACKGROUND
  A disintegrin and metalloprotease 8 (ADAM8) has been reported to be associated with various malignancies. However, no studies have examined ADAM8 association in colorectal cancer (CRC). The aim of this study was to investigate the expression and function of ADAM8 in CRC.
  
  
  METHODS
  Expression level of ADAM8 in CRC was evaluated by quantitative RT-PCR, western blot and immunohistochemical staining analysis. The role of ADAM8 in colorectal carcinogenesis was evaluated by in vitro assays. The correlations between ADAM8 status and clinicopathological features including survival were analyzed.
  
  
  RESULTS
  ADAM8 was highly expressed in CRC tissues compared with adjacent normal tissues. Knockdown of ADAM8 in two CRC cell lines resulted in reduced cellular growth and proliferation, and increased apoptosis. Immunohistochemistry analysis showed no significant correlations of ADAM8 protein expression with clinicopathologic features. Survival analysis indicated that patients with ADAM8-positive tumors had worse 5-year overall survival (OS, p = 0.037) and 5-year disease free survival (DFS, p = 0.014) compared with those with ADAM8-negative tumors. Multivariate analysis indicated ADAM8 expression was an independent prognostic factor for both OS and DFS (both p< 0.001). Subgroup analysis showed that 5-year OS of colon cancer, T3-T4 stage and N0 stage was worse for patients with ADAM8-positive tumors than those with ADAM8-negative tumors (p < 0.05). The 5-year DFS in colon cancer, T3-T4 stage, N0 stage, TNM stage II, adenocarcinoma, moderate differentiation and male patient subgroups was also worse for patients with ADAM8-positive tumors than those with ADAM8-negative tumors (p < 0.05).
  
  
  CONCLUSIONS
  Our results show that ADAM8 is overexpressed in CRC, promotes cell growth and correlates with worse OS and DFS, and thus could serve as a biomarker for individual CRC patient therapy.
authors.forename: Zuli
authors.initials: Z
authors.lastname: Yang
authors.forename: Yang
authors.initials: Y
authors.lastname: Bai
authors.forename: Lijun
authors.initials: L
authors.lastname: Huo
authors.forename: Hao
authors.initials: H
authors.lastname: Chen
authors.forename: Jintuan
authors.initials: J
authors.lastname: Huang
authors.forename: Jizheng
authors.initials: J
authors.lastname: Li
authors.forename: Xinjuan
authors.initials: X
authors.lastname: Fan
authors.forename: Zihuan
authors.initials: Z
authors.lastname: Yang
authors.affiliation: Department of Colon & Rectum Surgery, The Sixth Affiliated Hospital of Sun Yat-sen University (Guangdong Gastrointestinal and Anal Hospital), Sun Yat-Sen University Guangzhou, 26 YuancunErheng Road, Guangzhou, 510655, P,R China. leiwangyinghu@hotmail.com.
authors.forename: Lei
authors.initials: L
authors.lastname: Wang
authors.forename: Jianping
authors.initials: J
authors.lastname: Wang
mesh_terms: D051722:ADAM Proteins / Q000235:genetics* / Q000378:metabolism*; D000368:Aged; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D015179:Colorectal Neoplasms / Q000453:epidemiology* / Q000235:genetics / Q000473:pathology*; D005260:Female; D055785:Gene Knockdown Techniques; D019073:HT29 Cells; D006801:Humans; D008297:Male; D008565:Membrane Proteins / Q000235:genetics* / Q000378:metabolism*; D008875:Middle Aged; D009367:Neoplasm Staging; D012307:Risk Factors; D016019:Survival Analysis
chemical_list: D008565:Membrane Proteins; D051722:ADAM Proteins; C068490:ADAM8 protein, human
references.citation: EMBO Mol Med. 2014 Feb;6(2):278-94
references.pmid: 24375628
references.citation: J Cell Mol Med. 2007 Sep-Oct;11(5):1162-74
references.pmid: 17979891
references.citation: Pathol Oncol Res. 2013 Jan;19(1):79-88
references.pmid: 22965687
references.citation: Exp Cell Res. 2006 Feb 1;312(3):331-9
references.pmid: 16336960
references.citation: Virchows Arch. 2009 Apr;454(4):441-9
references.pmid: 19255780
references.citation: Clin Cancer Res. 2004 Dec 15;10(24):8363-70
references.pmid: 15623614
references.citation: Anticancer Agents Med Chem. 2012 Feb;12(2):163-71
references.pmid: 22043994
references.citation: J Urol. 2004 Dec;172(6 Pt 1):2162-6
references.pmid: 15538223
references.citation: Med Oncol. 2012 Sep;29(3):2032-7
references.pmid: 21983884
references.citation: Exp Oncol. 2008 Jun;30(2):129-32
references.pmid: 18566576
references.citation: Pathol Oncol Res. 2012 Jul;18(3):657-61
references.pmid: 22215309
references.citation: BMC Cancer. 2012 Feb 27;12:76
references.pmid: 22369429
references.citation: J Mol Med (Berl). 2010 May;88(5):497-505
references.pmid: 20119708
references.citation: Int J Surg Pathol. 2013 Apr;21(2):111-20
references.pmid: 22649166
references.citation: J Clin Oncol. 2005 Jan 20;23(3):609-18
references.pmid: 15659508
references.citation: J Neurosci. 2000 Nov 1;20(21):7964-71
references.pmid: 11050116
references.citation: Neurobiol Dis. 2007 Mar;25(3):665-74
references.pmid: 17207628
references.citation: Int J Cancer. 2009 Mar 15;124(6):1258-62
references.pmid: 19089928
references.citation: PLoS One. 2010 Jan 26;5(1):e8879
references.pmid: 20126641
references.citation: J Pathol. 2000 Dec;192(4):549-53
references.pmid: 11113875
references.citation: Int J Cancer. 2013 Apr 15;132(8):1851-9
references.pmid: 23011604
references.citation: Cancer Res. 2007 Aug 15;67(16):7703-12
references.pmid: 17699774
references.citation: Brain Res Brain Res Protoc. 2005 Dec;16(1-3):58-64
references.pmid: 16310404
references.citation: Cancer Res. 2011 Feb 1;71(3):1071-80
references.pmid: 21148749
references.citation: Int J Cancer. 2010 Jul 15;127(2):367-80
references.pmid: 19908233
references.citation: Oncogene. 2010 Jul 1;29(26):3758-69
references.pmid: 20453887
references.citation: Virchows Arch. 2006 Dec;449(6):628-36
references.pmid: 17106710
references.citation: J Neuropathol Exp Neurol. 2006 May;65(5):516-27
references.pmid: 16772875
references.citation: Cell Biol Int. 2013 Jan;37(1):47-53
references.pmid: 23319321
references.citation: J Natl Compr Canc Netw. 2011 Nov;9(11):1293-302
references.pmid: 22056657